Furthermore, GLP-1 has become the foundation of a novel class of peptide-based therapeutics for the treatment of diabetes and obesity (1), which is now evolving toward multimimetic molecules containing different degrees of GLP-1, GIP, and/or glucagon activity (2). Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.